Citations

Clear

144 citation(s) found for "Hopkins, David".

Antipsychotic Use in Bipolar Disorder: Clinical and Genomic Correlates– A Mayo Clinic Bipolar Disorder Biobank Study
Bond, David J. , Pendegraft, Richard S., Batzler, Anthony , Gardea-Reséndez, Manuel, Prieto, Miguel L. , Frye, Mark A. , Bond, David J , Singh, Balwinder , Ho, Ada Man‐Choi , Coombes, Brandon J. , Romo‐Nava, Francisco , Veldić, Marin , Cuéllar‐Barboza, Alfredo B. , Gardea‐Resendez, Manuel , Özerdem, Ayşegül , McElroy, Susan L. , Biernacka, Joanna M.

Mayo Clinic

No container title available | August 5, 2025 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-7274612/v1 | PMID 40799747 Get It

Abstract Background: Responsiveness to mood-stabilizing pharmacotherapy varies in bipolar disorder (BD). We investigated clinical correlates of second-generation antipsychotic (SGA) treatment response and conducted the first genome-wide association study (GWAS), including exploratory polygenic scores (PGS), of SGA pharmacogenomic treatment response in BD. Methods: Treatment response was quantified using the Alda scale, and GWAS was performed using Alda-A score, controlling for sex, genotyping batch, and the genomic principal components. Results: The cohort included 2,159 adults with BD (1,416 BD-I, 691 BD-II, 51 schizoaffective BD), mean age 41.8 years, 62% female, 84% white, and 14% Hispanic. Nearly half (48%) were treated with SGAs. Current SGA users were younger (41.2±14.7 vs. 42.5±15.3 years, p =0.040), more likely to be Hispanic (14% vs. 11%, p =0.047), had a higher body mass index (BMI; 30.4±7.6 vs. 29.5±7.1 kg/m 2 , p =0.005). Lifetime comorbidity patterns for current SGA users include higher rates of manic psychosis (29% vs. 17%, p <0.001) and eating disorders — Anorexia Nervosa (7% vs. 4%, p =0.003), Bulimia Nervosa (7% vs. 4%, p =0.003), and Binge Eating Disorder (14% vs. 11%, p =0.030). We detected a genome-wide significant association between SGA Alda-A scores and GAS7 variants (top variant: rs202127418, β =-2.998, p =4.96E-08). However, SGA response was not significantly associated with PGS for schizophrenia, BD, and major depression (FDR>0.05). Conclusions: SGAs are frequently utilized as mood stabilizers in patients with BD and are associated with manic psychosis and eating disorders. GAS7 variants may predict SGA response, but larger, more diverse cohorts are needed for validation.
A proposed clinical guide to delivering Lower Extremity Extracorporeal Distal Revascularization (LEEDR) as a bridge to definitive care in acute limb ischemia
Dvir, May , Jodłowski, Grzegorz , Stonko, David P. , Nelson, Jack, Morrison, Jonathan J. , Treffalls, Rebecca, Morrison, Jonathan J , Stonko, David P , Treffalls, Rebecca N. , Nelson, Jack, Walker, Patrick F.

Mayo Clinic

Perfusion | July 25, 2025 | Volume: 41 | Issue: 3 | Pages: 254-259

10.1177/02676591251363374 | PMID 40708295 Get It

Introduction Lower Extremity Extracorporeal Distal Revascularization (LEEDR) is a novel, preclinically tested technique designed to provide temporary limb perfusion in cases of acute limb ischemia when immediate revascularization is not feasible. Methods LEEDR employs an extracorporeal pump and circuit to draw arterial blood from a proximal inflow site and deliver it to an outflow artery within the ischemic limb. The system is designed for bedside initiation using percutaneous access. Results ALI from embolism, thrombosis, or trauma rapidly leads to irreversible tissue damage. Delays in revascularization are associated with high rates of limb loss and systemic complications. LEEDR offers a time-sensitive intervention aimed at mitigating these risks and preserving limb viability until definitive treatment is available. Conclusion LEEDR is a promising temporary perfusion strategy for limb salvage in ALI. This manuscript outlines its procedural components, technical considerations, and anticipated role in bridging patients to definitive revascularization.
23 | RADIOTHERAPY IMPROVES PROGRESSION‐FREE SURVIVAL FOR STAGE IA NLPHL: A RETROSPECTIVE REPORT FROM THE GLOBAL NLPHL ONE WORKING GROUP (GLOW)
Hartmann, S., Eich, Hans‐Theodor, Skinnider, Brian, Akhtar, Saad , Steiner, R., Milgrom, Sarah A. , Alomari, Mohammed H., Zhang, X., Wirth, A., Tsang, Rky, Smith, Sonali M. , Hendrickson, P., Hopkins, David , Ng, A., Koenig, Julie L. , Casulo, Carla , Sakthivel, GD, Roberts, Kenneth B. , Gao, Sarah , Alkendi, Jalila , Rahbi, Nasser Al, Balogh, Alex, Ricardi, U., Torka, Pallawi , Silva, Ravi De , Shah, Nimish , Osborne, Wendy , Henry, M M , Miall, Fiona , Brady, J.L. , Mikhaeel, G., Brennan, Barbara J. , Penn, Andrew M. , Reeves, Michael A., Terezakis, S., Kirova, Youlia , Fergusson, Pamela, Lee, Denise , Ku, Matthew , Mutsando, Howard , Tedjaseputra, Aditya , Gilbertson, Michael , Marconi, Tamara , Viiala, Nicholas , Natkunam, Y., Kelly, Kara M. , Borchmann, Peter , Hoppe, R T, Binkley, Michael S., Hopkins, David , Ku, Matthew , Flerlage, Jamie E. , Eichenauer, Dennis A. , Fuchs, M., Hartmann, S., Savage, Kerry J. , Hodgson, David C. , Rauf, M. Shahzad , Maghfoor, Irfan , Pinnix, Chelsea C. , Vega, Francisco , Alomari, M., Zhang, X., Collins, Graham P. , Advani, Ranjana H. , Kumar, P., Dickinson, Michael , Tsang, R., Prica, Anca A. , Major, Ajay , Kelsey, Chris R. , McKay, Pamela , Constine, Louis S , Casulo, Carla , Baron, J., Plastaras, John Peter , Levis, Mario , Sridhar, A., Specht, Lena , Pickard, Keir , Blazin, Lindsay , Henry, M., Chang, I., Smith, Christine M , Halperin, Daniel M. , Brennan, B., Penn, A., Senchenko, Maria Anatolevna , Volchkov, Egor Vasilevich , Hoppe, Bradford S. , Talaulikar, Dipti , Pepa, Roberta Della , Picardi, Marco , Fergusson, P., Northend, Michael , Hawkes, Eliza A. , Doo, Nicole Wong , Barraclough, Allison , Opat, Stephen , Cheah, Chan Y. , Salvaris, Ross , Hamad, Nada , Palese, M., Shankar, Ananth , Maurer, Matthew J. , Binkley, Michael S.

Mayo Clinic

Hematological Oncology | June 16, 2025 | Volume: 43 | Issue: S3 | Pages: No page available

10.1002/hon.70093_23 Get It

Dysregulated Tricarboxylic Acid Cycle Metabolism Is Associated With Right Ventricular Maladaptation in Pulmonary Vascular Disease
Rosen, Darin , Kolb, Todd M. , Mathai, Stephen C. , Suresh, Karthik , D’Amico, Rachel, Hsu, Steven , Tedford, Ryan J. , Hemnes, Anna R. , Leopold, Jane A. , Horn, Evelyn M. , Erzurum, Serpil C. , Beck, Gerald J. , Hill, Nicholas S. , Farha, Samar , Grünig, Gabriele , Jellis, Christine , Kwon, Deborah , Park, Margaret , Xiao, L, Fessel, Jeffrey , Fu, Yongping , Postow, Lisa, Schmetter, Barry, Sutliff, R, Tian, Xuefei , Joseloff, Elizabeth, Wong, Brenda , Lawler, Laurie, Maron, B, Haythe, Jennifer , Krishnan, Udhay , Payne, David A., Bergman, Geoffrey , Bastert, K, Devereux, Richard B. , Kim, Ju Youn , Lohman, Julia, Racanelli, Alexandra C. , Ricketts, Michelle L., Sobol, Irina , Singh, Harsimran , Weinsaft, Jonathan W. , Mathai, S.C. , Carey, Kyle A. , Damico, Rachel L. , Enobun, Blessing , Sanni, Y, Brock, Heinz, Durst, Louise A., Head, Denise , Foley, Thomas A. , Gochanour, Benjamin R. , Halbach, H, Krowka, Michael J. , Menon, David K. , Park, Gyu Tae , Redfield, Margaret M. , Rohwer, Kristi, Williamson, Eric E. , Vanderpool, R, Yuan, Jason X.‐J. , Lim, C.S., Abidov, Aiden , Erickson, Harold , Cunningham, James M. , Pugh, Meredith E., Robbins, Ivan M. , Beck, Gerald J. , Aldred, Micheala A. , Asosingh, Kewal, Aylor, Joan, Beck, B, Borowski, A, Collart, Clara, Comhair, S.A.A., Drinko, Jeanne K., Finet, J. Emanuel , Flinn, Aisling M. , Geraci, M, Jacob, Miriam , Kanta, Alexandra, Larive, Brett , Lempel, Jason K. , Li, Minghui , MacKrell, J., Neumann, D., Nawabit, R, Odabashian, Jill, Olman, Mitchell A. , Park, M, Radeva, Milena , Renapurkar, R, Sharp, Jacqueline, Sherer, Stefan, WHW, Tang, Thomas, Jason , Wadih, K, Wells, Simon P. , Wilcox, Jane, Yu, S, Rounds, Sharon , Bull, Todd , Cadigan, John B., Rosen, Darin T , Rosenzweig, Erika B , Rischard, Franz P , Frantz, Robert P , Beck, Gerald J , Hill, Nicholas S , Barnard, John , Grunig, Gabriele , Jellis, Christine L , Kwon, Deborah H , Mehra, Reena , Park, Margaret M , Tang, W H Wilson , Hassoun, Paul M , Simpson, Catherine E , Hemnes, Anna , Horn, Evelyn M , Leopold, Jane A , Tedford, Ryan J , Mathai, Stephen C , Hsu, Steven , Rosenzweig, Erika B. , Rischard, Franz , Frantz, Robert P. , Barnard, John , Mehra, Reena , Tang, W.H. Wilson , Hassoun, Paul M. , Simpson, Catherine E. , Xiao, L, Fu, Y‐P, Gray, Michael P. , Wong, B, Waxman, Aaron B. , Systrom, David M , Brady, David J. , Chung, Wendy K. , Payne, D, Karas, Maria , Lohman, J, Ricketts, M, Balasubramanian, A, Carey, K, Gao, Lei , Halushka, Marc K. , Kass, David A. , Lin, Ting‐Tse , Mukherjee, Monica , Roth, J, Sanni, Y, Weiss, Robert E. , Zimmerman, Stefan L , Behfar, Atta , Borlaug, Barry A. , Brock, H Du, Head, D, Kane, Garvan C. , Sands, T. , Scott, Christopher G. , Terzic, André , Williamson, E, Garcia, Joe G. N. , Lim, C, Desai, Akshay S , Hansen, L, Newman, J, Brittain, Evan L , Cheng, Feixiong , Filippo, F Di, Flinn, A, Hu, Bo , Jaber, Wael A. , Kanta, A, Martín, Maite Velázquez , McCarthy, Kevin , Ramos, J, Wiggins, K, Willard, Belinda B. , Benza, Raymond L. , Fang, James C. , Gomberg‐Maitland, Mardi

Mayo Clinic

Journal of the American Heart Association | May 22, 2025 | Volume: 14 | Issue: 11 | Pages: No page available

10.1161/jaha.124.041127 | PMID 40401597 Get It

Background Right ventricular (RV) maladaptation to elevated pulmonary afterload is the primary determinant of outcomes in pulmonary artery (PA) hypertension; however, the pathobiological mechanisms underlying RV decompensation remain poorly understood. Methods We performed global untargeted metabolomics on plasma from 55 patients who underwent gold‐standard RV‐PA coupling measurements using multibeat pressure volume loop assessment in a single‐center cohort and from 1027 patients with coupling surrogate measurements in a larger multicenter cohort, the PVDOMICS (Pulmonary Vascular Disease Phenomics) study. Age and sex‐adjusted linear regression was performed to identify associations between metabolites and coupling metrics. Additionally, we performed a metabolic flux analysis using gene expression data from RV tissue in an independent cohort of 32 patients. Partial least squares–discriminant analysis was used to identify metabolites and reactions characteristic of the decompensated RV. Results RV‐PA coupling was negatively associated with tricarboxylic acid (TCA) cycle intermediate levels. Specifically, plasma α‐ketoglutarate and fumarate were significantly associated with all coupling metrics in both cohorts. Metabolic flux analysis indicated that decompensated RVs exhibited aberrant TCA cycle activity, including reduced acetyl coenzyme A entry and increased lactate elimination, suggesting a shift from the TCA cycle toward glycolysis at the RV tissue level. Conclusions We identify an association between circulating TCA cycle intermediate levels and RV‐PA uncoupling in 2 independent cohorts, and dysregulated TCA cycle metabolism in decompensated PA hypertension RVs, suggesting that aberrant TCA cycle metabolism could represent a hallmark of RV maladaptation in PA hypertension. Further study of this pathway is warranted to develop novel biomarkers of RV function or RV‐targeted therapies.
The International Classification of Vestibular Disorders: Achievements, challenges, and future directions
Kaski, Diego , Tarnutzer, Alexander A. , Carey, John P. , Cha, Yoon‐Hee , Eggers, Scott D.Z. , Furman, Joseph M. , Kim, Hyun Ah , Lempert, Thomas , López‐Escámez, José A. , Magnusson, Måns , Newman‐Toker, David E. , Seemungal, Barry M. , Berg, Raymond van de , Brevern, Michael von , Bisdorff, Alexandre , Cha, Y H , Eggers, Scott Dz, Lempert, Thomas , López-Escámez, Jose A , Magnusson, Mans , Newman-Toker, David E , Seemungal, Barry M , Staab, Jeffrey P , Agrawal, Yuri , Kim, Ji‐Soo , Staab, Jeffrey P. , Strupp, Michael Leo , Ward, Bryan Kevin

Mayo Clinic

Journal of Vestibular Research | May 17, 2025 | Volume: 35 | Issue: 3 | Pages: 105-112

10.1177/09574271251313803 | PMID 39973600 Get It

In 2007, the Bárány Society embarked on a project to establish definitions of vestibular syndromes and disorders based on best available evidence, referred to as the International Classification of Vestibular Disorders (ICVD). Since then, numerous publications providing consensus-driven diagnostic criteria for vestibular symptoms, syndromes, and disorders have been published. Here, we reflect on the rationale for developing the ICVD as well as its subsequent achievements, challenges, and outlook. In this summary of the work of the ICVD to date, the authors will focus on practical aspects to help improve the utility and applicability of these diagnostic criteria moving forward.
Performance of open versus endovascular approaches in swine modeling of acute mesenteric ischemia
Banaskiewicz, Karolina , Wilken, Silvana, Stonko, David P. , Morrison, Jonathan J. , Treffalls, Rebecca, Stonko, David P , Morrison, Jonathan J , Treffalls, Rebecca N.

Mayo Clinic

Vascular | April 26, 2025 | Volume: 34 | Issue: 2 | Pages: 351-356

10.1177/17085381251339240 | PMID 40285791 Get It

Objectives Traditionally, acute mesenteric ischemia studies are performed by utilizing an open superior mesenteric artery (SMA) occlusion, which is an invasive technique with potentially devastating effects. A new endovascular technique for SMA occlusion using a catheter-balloon system was designed and compared to the open SMA occlusion to test its efficacy and animal safety. Methods All animals underwent open instrumentation of the superior mesenteric vein (SMV) for blood flow monitoring. The animals were grouped into an open SMA occlusion technique group and an endovascular SMA occlusion group. The open SMA occlusion technique group involved exposure of the SMA via left medial visceral rotation with vascular clamping. In the endovascular group, an endovascular balloon was placed in the SMA and inflated to produce occlusion. Results Complete cessation of flow to the SMV was observed in the endovascular group, compared to the residual SMV flow in the open occlusion group. Following a 30-min post-occlusion period, the MAP in the endovascular group increased, compared to a decline of MAP in the open occlusion group. Conclusions This study indicates the endovascular technique provides a more potent SMA occlusion, with insignificant consequences on the overall health of the animal, in contrast to the open vascular clamping.
Abstract LB331: Enhanced polygenic risk score for pancreatic cancer
Antwi, Samuel O. , Atkinson, Hunter J., Zhong, Jun, McKean, David , PanC4), Pancreatic Cancer Cohort & Case Control Consortia (PanScan and, Wolpin, Brian M. , Oberg, Ann L. , Antwi, Samuel O , Coombes, Brandon J. , Larson, Nicholas B. , Carlson, Erin E. , Rabe, Kari G. , Majumder, Shounak , PanC4), Pancreatic Cancer Cohort & Case Control Consortia (PanScan and, Stolzenberg‐Solomon, Rachael Z. , Klein, Alison P. , Ámundadóttir, Laufey T.

Mayo Clinic

Cancer Research | April 25, 2025 | Volume: 85 | Issue: 8_Supplement_2 | Pages: LB331-LB331

10.1158/1538-7445.am2025-lb331 Get It

Abstract Background: Pancreatic ductal adenocarcinoma (PDAC) is the third leading cause of cancer-related deaths in the U.S. mainly because of late-stage diagnosis. Heritable genetic information can improve risk stratification for individuals with moderate to high-risk of PDAC for targeted screening and early detection. We aimed to develop an enhanced polygenic risk score (PRS) for PDAC using a Bayesian approach, LDpred2, that reweights risk estimates attributed to millions of polymorphisms (SNPs) estimated from genome-wide association studies (GWASs). We then compared the performance of LDpred2 with the commonly used genetic risk score (GRS) approach that is based only on genome-wide significant SNPs. Methods: GWAS summary statistics were obtained from the Pancreatic Cancer Cohort Consortium and the Pancreatic Cancer Case Control Consortium for 9040 cases and 12496 controls and were used to compute weights for a GRS (17 SNPs) using a p-value threshold of 5e-8 and weights for an enhanced PRS (1.3 million SNPs) using LDpred2. These weights were then used to compute risk scores in an independent validation sample of 2616 cases and 45407 controls from the Mayo Clinic. We used logistic regression to test for associations of the GRS and PRS with PDAC risk, adjusting for age, sex, and the first 10 principal components of ancestry. Results: The validation sample was of mostly European ancestries (&gt;95%). Cases were slightly older than controls (median age: 66 yrs. vs. 63 yrs.) and had a higher frequency of men than controls (57% vs. 42%). Comparisons between the GRS and the PRS are shown in Table 1. DeLong’s test comparing the AUCs between the two genetic scores showed the PRS significantly outperformed the GRS (AUC = 0.68 vs. 0.67; p = 7.6e-7). Conclusions: The LDpred2 PRS model that used a larger set of SNPs significantly improved prediction of PDAC. Comparing the top percentile of the PRS versus the rest showed that the PRS is a clinically significant risk score (OR &gt; 3) for PDAC and could inform clinical decision making and genetic counseling of individuals identified as having a high risk of PDAC. Citation Format: Samuel O. Antwi, Brandon J. Coombes, Nicholas B. Larson, Erin E. Carlson, Kari G. Rabe, Hunter J. Atkinson, Shounak Majumder, Jun Zhong, David McKean, Pancreatic Cancer Cohort & Case Control Consortia (PanScan and PanC4), Brian M. Wolpin, Rachael Z. Stolzenberg-Solomon, Alison P. Klein, Laufey T. Amundadottir, Ann L. Oberg. Enhanced polygenic risk score for pancreatic cancer [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2025; Part 2 (Late-Breaking, Clinical Trial, and Invited Abstracts); 2025 Apr 25-30; Chicago, IL. Philadelphia (PA): AACR; Cancer Res 2025;85(8_Suppl_2):Abstract nr LB331.
Development of a Core Critical Care Data Dictionary With Common Data Elements to Characterize Critical Illness and Injuries Using a Modified Delphi Method
Anderson, Wesley R., Heavner, Smith H., Al-Hakim, Tamara, Cruz‐Cano, Raul , Engel, Heidi J., Lamb, Keith, MacLaren, Robert , Rincon, Teresa , Sikora, Andrea, Tanner, Donna, Teeter, William , Wong, An-Kwok Ian , Zhang, Xiaohan Tanner , Zimmerman, Jerry J. , Kumar, Vishakha K. , Cobb, J. Perren, Laudański, Krzysztof , Murphy, David J., Anderson, Wesley, Heavner, Smith H., Kamaleswaran, Rishikesan , Badawi, Omar , Grunwell, Jocelyn R. , Herasevich, Vitaly , Khanna, Ashish K. , Sanchez-Pinto, Lazaro Nelson , Sikora, Andrea , Stevens, Robert David , Wynn, James Lawrence , Reuter‐Rice, Karin

Mayo Clinic

Critical Care Medicine | February 21, 2025 | Volume: 53 | Issue: 5 | Pages: e1045-e1054

10.1097/ccm.0000000000006595 | PMID 39982128 Get It

OBJECTIVES: To develop the first core Critical Care Data Dictionary (C2D2) with common data elements (CDEs) to characterize critical illness and injuries. DESIGN: Group consensus process using modified Delphi approach. SETTING: Electronic surveys and in-person meetings. SUBJECTS: A multidisciplinary workgroup of clinicians and researchers with expertise in the care of the critically ill and injured. INTERVENTIONS: The Delphi process was divided into domain and CDE portions with each composed of two item generation rounds and one item reduction/refinement rounds. Two in-person meetings augmented this process to facilitate review and consideration of the domains and by panel members. The final set of domains and CDEs was then reviewed by the group to meet the competing criteria of utility and feasibility, resulting in the core dataset. MEASUREMENTS AND MAIN RESULTS: The 23-member Delphi panel was provided 1833 candidate variables for potential dataset inclusion. The final dataset includes 226 patient-level CDCs in nine domains, which include anthropometrics and demographics (8), chronic comorbid illnesses (18), advanced directives (1), ICU diagnoses (61), diagnostic tests (42), interventions (27), medications (38), objective assessments (26), and hospital course and outcomes (5). Upon final review, 91% of the panel endorsed the CDCs as meeting criteria for a minimum viable data dictionary. Data elements cross the lifespan of neonate through adult patients. CONCLUSIONS: The resulting C2D2 provides a foundation to facilitate rapid collection, analyses, and dissemination of information necessary for research, quality improvement, and clinical practice to optimize critical care outcomes. Further work is needed to validate the effectiveness of the dataset in a variety of critical care settings.
The problem with the existing reporting standards for adverse event and medical error research
Carpenter, Christopher R. , Griffey, Richard T. , Unbeck, Maria , Adler, Lee, Stockwell, David C. , Classen, David C. , Unbeck, Maria , Stockwell, David C , Carpenter, Christopher R , Griffey, Richard T , Rutjes, Anne WS

Mayo Clinic

BMJ Quality & Safety | February 11, 2025 | Volume: 34 | Issue: 4 | Pages: 273-278

10.1136/bmjqs-2024-017491 | PMID 39933922 Get It

The Enhancing the Quality and Transparency of Health Research (EQUATOR) Network indexes over 600 reporting guidelines designed to improve the reproducibility of manuscripts across medical fields and study designs. Although several such reporting guidelines touch on adverse events that may occur in the context of a study, there is a large body of research whose primary focus is on adverse events, near-misses and medical errors that do not currently have a dedicated reporting guideline to help set reporting standards and facilitate comparisons across studies. As part of the process prescribed by EQUATOR for developing such a reporting guideline, we performed a needs assessment, evaluating whether existing standards address key features of a proposed reporting guideline in development, entitled Standard Elements in Studies of Adverse Events and Medical Error (SESAME). We evaluated 12 EQUATOR reporting guidelines for the presence of eight key features of SESAME. Five of the 12 failed to include any of these key features. None of the remaining seven incorporated more than four of the eight SESAME key components, confirming the need for a dedicated reporting guideline for studies of adverse events and medical errors.
Benchmarking the efficacy of salvage systemic therapies for recurrent meningioma: A RANO group systematic review and meta-analysis to guide clinical trial design
Kotecha, Rupesh , Akdemir, Eyüb Yaşar , Blakeley, Jaishri O. , Dixit, Karan , Dunn, Ian F. , Galanis, Evanthia , Kurz, Sylvia C. , McDermott, Michael , Odia, Yazmín , Raizer, Jeffrey, Reardon, David A. , Rogers, Leland , Schiff, David , Vogelbaum, Michael A., Wen, Patrick Y. , Akdemir, Eyub Y , Blakeley, Jaishri O , Galanis, Evanthia , Galldiks, Norbert , Weller, Michael , Wen, Patrick Yung , Odia, Yazmin , Kütük, Tuğçe , Ilgın, Can , Ahluwalia, Manmeet S. , Bi, Wenya Linda , Huang, Raymond Y. , Johnson, Derek R. , Kaley, Thomas , Kamson, David , Preusser, Matthias , Rudà, Roberta , Mehta, Minesh P. , McDermott, Michael W.

Mayo Clinic

Neuro-Oncology | January 10, 2025 | Volume: 27 | Issue: 7 | Pages: 1670-1685

10.1093/neuonc/noaf009 | PMID 39807850 Get It

Abstract Background Despite advances in our understanding of the molecular underpinnings of meningioma progression and innovations in systemic and local treatments, recurrent meningiomas remain a substantial therapeutic challenge. The objective of this systematic review and meta-analysis is to provide a historical baseline, contemporary analysis, and propose a “rate of probable interest” to inform future clinical trial design and development on behalf of the Response Assessment in Neuro-Oncology meningioma group. Methods PubMed, ClinicalTrials.gov, and ASCOpubs databases were screened for clinical trials evaluating the activity of systemic therapies for adults with recurrent meningiomas. The pooled progression-free survival at 6-months and 1-year (PFS-6 and PFS-1 year) values were calculated using the random effects technique with I2 indices. Results The pooled PFS-6 and PFS-1 year rates for recurrent WHO grade 1 meningiomas were 43.6% (95% CI: 22.7-67.0%, I2 = 80%) and 21.7% (95% CI: 6.2-53.9%, I2 = 76%), and for grades 2-3 meningiomas, the PFS-6 was 38.0% (95% CI: 28.3-48.8%, I2 = 68%). In the targeted therapy group, PFS-6 and PFS-1 year rates stood at 62.0% (I2 = 58%) and 49.0% (I2 = 63%) for grade 1, while for grades 2-3 tumors, the PFS-6 rates with targeted therapy and immunotherapy were 42.1% (I² = 60%) and 46.0% (I² = 0%), respectively. The benchmarks were set at 67% and 54% for PFS-6 and PFS-1 year for grade 1 tumors, and PFS-6 of 49% for grades 2-3 tumors. Conclusions Several studies have reported outcomes in patients with recurrent meningiomas testing a variety of agents with modest, but variable and progressively increasing activity. In this context, we recommend new benchmarks for future trials to define efficacy of future investigational therapies.